Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Apogee Enterprises Inc. (NASDAQ: APOG) shares declined 1.00 percent to close at $30.56 a share Wednesday. The stock traded between $30.36 and $30.90 on volume of 205,074 shares traded. Goldman Sachs has recently initiated coverage on the company with a "buy" rating and a price target of $38.00. Shares of Apogee Enterprises have gained approximately 27.0 percent year-to-date.
Get more information on Apogee Enterprises and free access to the in-depth equity report at:
www.FiveStarEquities.com/APOG
Molycorp Inc. (NYSE: MCP) shares spiked 10.51 percent to close at $7.36 a share Wednesday. The stock traded between $6.94 and $7.59 on volume of 18.97 million shares traded. The company announced that the chloralkali plant at Mountain Pass, California, is now mechanically complete and that full-scale commissioning operations have commenced. Shares of Molycorp have fallen approximately 22.0 percent year-to-date.
Get more information on Molycorp and free access to the in-depth equity report at:
www.FiveStarEquities.com/MCP
Merit Medical Systems, Inc. (NASDAQ: MMSI) shares increased 1.52 percent to close at $12.69 a share Wednesday. The stock traded between $12.68 and $13.71 on volume of 405,786 shares traded. Raymond James has upgraded its rating on the company to "strong buy" from "market perform". Shares of Merit Medical Systems have declined approximately 8.0 percent year-to-date.
Get more information on Merit Medical Systems and free access to the in-depth equity report at:
www.FiveStarEquities.com/MMSI
Zogenix, Inc. (NASDAQ: ZGNX) shares surged 14.87 percent to close at $2.24 a share Wednesday. The stock traded between $2.16 and $2.52 on volume of 5.40 million shares traded. The company announced that the FDA has informed them that an action letter on the New Drug Application for Zohydro ER "could follow after a further delay of short duration." Shares of Zogenix have gained approximately 68.0 percent year-to-date.
Get more information on Zogenix free access to the in-depth equity report at:
www.FiveStarEquities.com/ZGNX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com